0001091818-24-000134.txt : 20241108 0001091818-24-000134.hdr.sgml : 20241108 20241108113425 ACCESSION NUMBER: 0001091818-24-000134 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241108 DATE AS OF CHANGE: 20241108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOFORCE NANOSCIENCES HOLDINGS, INC. CENTRAL INDEX KEY: 0001310488 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 852138858 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51074 FILM NUMBER: 241438812 BUSINESS ADDRESS: STREET 1: 2020 GENERAL BOOTH BLVD STREET 2: SUITE 230 CITY: VIRGINIA BEACH STATE: VA ZIP: 23454 BUSINESS PHONE: 757-306-6090 MAIL ADDRESS: STREET 1: 2020 GENERAL BOOTH BLVD STREET 2: SUITE 230 CITY: VIRGINIA BEACH STATE: VA ZIP: 23454 FORMER COMPANY: FORMER CONFORMED NAME: SILVER RIVER VENTURES, INC. DATE OF NAME CHANGE: 20041202 10-Q 1 bfnh20240930_10q.htm QTR. REPORT - SEPT. 2024
false 2024 Q3 --12-31 0001310488 0001310488 2024-01-01 2024-09-30 0001310488 2024-11-07 0001310488 2024-09-30 0001310488 2023-12-31 0001310488 2024-07-01 2024-09-30 0001310488 2023-07-01 2023-09-30 0001310488 2023-01-01 2023-09-30 0001310488 2022-12-31 0001310488 2023-09-30 0001310488 us-gaap:CommonStockMember 2022-12-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001310488 us-gaap:RetainedEarningsMember 2022-12-31 0001310488 us-gaap:CommonStockMember 2023-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001310488 us-gaap:RetainedEarningsMember 2023-03-31 0001310488 2023-03-31 0001310488 us-gaap:CommonStockMember 2023-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001310488 us-gaap:RetainedEarningsMember 2023-06-30 0001310488 2023-06-30 0001310488 us-gaap:CommonStockMember 2023-12-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001310488 us-gaap:RetainedEarningsMember 2023-12-31 0001310488 us-gaap:CommonStockMember 2024-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001310488 us-gaap:RetainedEarningsMember 2024-03-31 0001310488 2024-03-31 0001310488 us-gaap:CommonStockMember 2024-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001310488 us-gaap:RetainedEarningsMember 2024-06-30 0001310488 2024-06-30 0001310488 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001310488 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001310488 2023-01-01 2023-03-31 0001310488 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001310488 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001310488 2023-04-01 2023-06-30 0001310488 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001310488 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001310488 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001310488 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001310488 2024-01-01 2024-03-31 0001310488 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001310488 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001310488 2024-04-01 2024-06-30 0001310488 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001310488 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001310488 us-gaap:CommonStockMember 2023-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001310488 us-gaap:RetainedEarningsMember 2023-09-30 0001310488 us-gaap:CommonStockMember 2024-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001310488 us-gaap:RetainedEarningsMember 2024-09-30 0001310488 2020-05-01 2020-05-06 0001310488 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001310488 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001310488 2019-11-01 2019-11-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2024

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 000-51074

 

 

BIOFORCE NANOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Commission file number: 000-53505

 

Nevada 74-3078125
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
   
2020 General Booth Blvd., Unit 230
Virginia Beach, VA
(principal executive offices)
23454
(Zip Code)

 

Registrant's telephone number, including area code: (757) 306-6090

 

Securities registered under Section 12(b) of the Exchange Act: None
   
Securities registered under Section 12(g) of the Exchange Act: Common stock, par value $0.001 per share
  (Title of class)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer ☐

Non-accelerated filer

Emerging growth company

Accelerated filer ☐

Smaller reporting company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
NONE   NONE   NONE

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: At November 7, 2024 the registrant had outstanding 29,271,755 shares of common stock, par value $0.001 per share.

 

 -1- 

 

 

TABLE OF CONTENTS

 

    PAGE
PART I    
Item 1. Condensed Consolidated Unaudited Financial Statements 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 10
Item 3. Quantitative and Qualitative Disclosures About Market Risk 14
Item 4. Controls and Procedures 14
PART II    
Item 1. Legal Proceedings 15
Item 1A. Risk Factors 15
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
Item 3. Defaults Upon Senior Securities 15
Item 4. Mining Safety Disclosures 16
Item 5. Other Information 16
Item 6. Exhibits 16
  Signatures 16

 

 -2- 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

BIOFORCE NANOSCIENCES HOLDINGS, INC.

 
FINANCIAL REPORTS
AT
September 30, 2024

 

INDEX TO FINANCIAL STATEMENTS

 

Condensed Consolidated Balance Sheets at September 30, 2024 Unaudited and December 31, 2023 4
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 - Unaudited 5
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 - Unaudited 6
Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023-Unaudited 7
Notes to the Condensed Consolidated Unaudited Financial Statements 8-9

 

 -3- 

 

 

BioForce Nanosciences Holdings, Inc., and Subsidiary
 
CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED

 

   September 30,   December 31, 
   2024   2023 
ASSETS          
Current Assets          
Cash  $1,635   $638 
           
Total Current Assets   1,635    638 
           
Total Assets  $1,635   $638 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
Current Liabilities          
Accounts Payable and Accrued Expenses  $6,261   $2,649 
Accrued Board of Directors Compensation   1,913,767    1,596,517 
Due to Related Parties   260,039    220,702 
           
Total Current Liabilities   2,180,067    1,819,868 
           
Total Liabilities   2,180,067    1,819,868 
           
Stockholders' Deficit          
Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 29,271,755 Issued and Outstanding, Respectively   29,272    29,272 
Additional Paid-In-Capital   158,789,302    158,781,227 
Accumulated Deficit   (160,997,006)   (160,629,729)
           
Total Stockholders' Deficit   (2,178,432)   (1,819,230)
           
Total Liabilities and Stockholders' Deficit  $1,635   $638 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 -4- 

 

 

BioForce Nanosciences Holdings, Inc., and Subsidiary
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

 

                     
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2024   2023   2024   2023 
Sales  $-   $-   $-   $- 
                     
Cost of Sales   -    -    -    - 
                     
Gross Profit   -    -    -    - 
                     
Operating Expenses                    
Board of Directors Compensation   105,750    105,750    317,250    317,250 
General and Administrative   16,274    7,857    50,027    40,293 
                     
Total Expenses   122,024    113,607    367,277    357,543 
                     
Net Loss for the Period  $(122,024)  $(113,607)  $(367,277)  $(357,543)
                     
Weighted Average Number of Common Shares - Basic and Diluted   29,271,755    29,271,755    29,271,755    29,271,755 
                     
Net Loss for the Period Per Common Shares - Basic and Diluted  $(0.00)  $(0.00)  $(0.01)  $(0.01)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 -5- 

 

 

BioForce Nanosciences Holdings, Inc., and Subsidiary
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED

 

           
For the Nine Months Ended September 30,  2024   2023 
         
Cash Flows from Operating Activities          
           
Net Loss for the Period  $(367,277)  $(357,543)
           
Changes in Assets and Liabilities:          
Accounts Payable and Accrued Expenses   3,612    677 
Accrued Board of Directors Compensation   317,250    317,250 
           
Net Cash Flows Used In Operating Activities   (46,415)   (39,616)
           
Cash Flows from Investing Activities   -    - 
           
Cash Flows from Financing Activities          
Captial Contributions   8,075    - 
Proceeds from Related Parties   39,337    39,568 
           
Net Cash Flows Provided by Financing Activities   47,412    39,568 
           
Net Change in Cash   997    (48)
           
Cash - Beginning of Period   638    734 
           
Cash - End of Period  $1,635   $686 
           
Cash Paid During the Period for:          
Interest  $-   $- 
Income Taxes  $-   $- 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 -6- 

 

 

BioForce Nanosciences Holdings, Inc., and Subsidiary
 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT FOR THE THREE AND NINE MONTHS ENDED

SEPTEMBER 30, 2024 AND 2023

UNAUDITED

 

                          
   Common Stock   Additional       Total 
   $ 0.001 Par   Paid-In   Accumulated   Stockholders' 
   Shares   Amount   Capital   Deficit   Deficit 
Balance - January 1, 2023   29,271,755   $29,272   $158,781,227   $(160,157,776)  $(1,347,277)
                          
Net Loss for the Period   -    -    -    (130,005)   (130,005)
                          
Balance - March 31, 2023   29,271,755    29,272    158,781,227    (160,287,781)   (1,477,282)
                          
Net Loss for the Period   -    -    -    (113,931)   (113,931)
                          
Balance - June 30, 2023   29,271,755    29,272    158,781,227    (160,401,712)   (1,591,213)
                          
Net Loss for the Period   -    -    -    (113,607)   (113,607)
                          
Balance - September 30, 2023   29,271,755   $29,272   $158,781,227   $(160,515,319)  $(1,704,820)

 

   Common Stock   Additional       Total 
   $ 0.001 Par   Paid-In   Accumulated   Stockholders' 
   Shares   Amount   Capital   Deficit   Deficit 
Balance - January 1, 2024   29,271,755   $29,272   $158,781,227   $(160,629,729)  $(1,819,230)
                          
Net Loss for the Period   -    -    -    (130,813)   (130,813)
                          
Balance - March 31, 2024   29,271,755   $29,272   $158,781,227   $(160,760,542)  $(1,950,043)
                          
Captial Contributions   -    -    75    -    75 
                          
Net Loss for the Period   -    -    -    (114,440)   (114,440)
                          
Balance - June 30, 2024   29,271,755    29,272    158,781,302    (160,874,982)   (2,064,408)
                          
Captial Contributions   -    -    8,000    -    8,000 
                          
Net Loss for the Period   -    -    -    (122,024)   (122,024)
                          
Balance - September 30, 2024   29,271,755   $29,272   $158,789,302   $(160,997,006)  $(2,178,432)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 -7- 

 

 

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

 

 

NOTE 1 – Organization & Description of Business

 

The Company was incorporated in the State of Nevada on December 10, 1999 as Silver River Ventures, Inc. On February 24, 2006, the Company completed the acquisition of BioForce Nanosciences Holdings Inc. (“BioForce”), a Delaware corporation, and changed the corporate name at that time. On May 6, 2020, the Company purchased 100,000 shares of Element Acquisition Corporation for $1,000 which then became a wholly owned subsidiary. On October 15, 2020, the Company’s wholly-owned subsidiary changed its name from Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc, a Wyoming corporation. On December 14, 2021, the Company’s wholly-owned subsidiary changed its name from BioForce Nanosciences Holdings, Inc., a Wyoming corporation to Element Global Inc., a Wyoming corporation. The Company’s mission is to become a leading provider of vitamin, mineral and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges.

 

NOTE 2 – Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed consolidated balance sheet has been derived from the December 31, 2023 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2024 and 2023, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results of operations expected for the year ending December 31, 2024.

 

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Earnings (Loss) per Share

 

Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share.

 

Stock-Based Compensation 

 

We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation—Stock Compensation, which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values.  The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.

 

Fair Value of Financial Instruments

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates.

 

 -8- 

 

 

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

 

 

NOTE 2 – Summary of Significant Accounting Policies - continued

 

Revenue Recognition

 

The Company implemented ASC 606, Revenue from Contracts with Customers. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.

 

The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.

 

NOTE 3 – Recently Issued Accounting Standards

 

The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements, including the new lease standard. The Company does not have any leases and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

NOTE 4 – Going Concern 

 

The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has reported recurring losses from operations and has net current liabilities and an accumulated deficit. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.

 

While the Company is attempting to continue operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management believes that the actions presently being taken to further implement the Company’s business plan; to expand sales with a dynamic marketing campaign and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. During the nine months ended September 30, 2023 due to lack of revenues the officers of the Company paid for all expenses through loans to the Company. This allowed the Company to continue as a going concern.

 

NOTE 5 – Related Party Transactions

 

The Company’s Director, Secretary and Acting CFO, Richard Kaiser, is the operator of Yes International, a full-service investor relations firm. He handles duties of the Company regarding his officer capacities as the Secretary and Acting CFO, but also provides investor relations services through Yes International for the Company at no charge.

 

During the nine months ended September 30, 2024 and 2023, two board of directors paid expenses of the Company in the amount of $39,338 and $39,568, respectively. Due to related parties was $260,039 and $213,664 at September 30, 2024 and 2023, respectively.

 

NOTE 6 – Stock

 

Preferred Stock

 

Preferred stock consists of 100,000,000 shares authorized at $0.001 par value. 10,000,000 of these preferred shares have been separately allocated to Series A Preferred. Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock. At September 30, 2024 and December 31, 2023, there were -0- Series A Preferred shares issued and outstanding.

 

Common Stock

 

Common stock consists of 900,000,000 shares authorized at $0.001 par value. On November 25, 2019, the board of directors approved a 5 to 1 reverse split. At September 30, 2024 and December 31, 2023, there were 29,271,755 shares issued and outstanding, respectively.

 

 -9- 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following information should be read in conjunction with our financial statements and related notes thereto included in Part I, Item 1, above.

 

Forward Looking Statements

 

Certain matters discussed herein are forward-looking statements. Such forward-looking statements contained in this Form 10-Q involve risks and uncertainties, including statements as to:

 

· our future strategic plans

· our future operating results;

· our business prospects;

· our contractual arrangements and relationships with third parties;

· the dependence of our future success on the general economy;

· our possible future financing; and

· the adequacy of our cash resources and working capital.

 

From time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Such forward-looking statements may be included in, but not limited to, press releases, oral statements made with the approval of an authorized executive officer or in various filings made by us with the Securities and Exchange Commission. Words or phrases "will likely result", "are expected to", "will continue", "is anticipated", "estimate", "project or projected", or similar expressions are intended to identify "forward-looking statements". Such statements are qualified in their entirety by reference to and are accompanied by the above discussion of certain important factors that could cause actual results to differ materially from such forward-looking statements.

 

The risks identified here are not all inclusive. New risk factors emerge from time to time and it is not possible for management to predict all of such risk factors, nor can it assess the impact of all such risk factors on the company's business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results.

The financial information set forth in the following discussion should be read with the financial statements of BioForce NanoSciences Holdings, Inc. included elsewhere herein.

 

Business

 

BioForce Nanosciences Holdings, Inc. (“BioForce or the “Company”) was previously in the business of manufacturing nano-particular measurement devices and molecular printers, but due to a lack of profitability, the subsidiary of the company that owned that technology filed for bankruptcy. That subsidiary and related technology was later bought out of bankruptcy by an unrelated third party. Subsequently, new management came into the Company to pursue a better business model and now the Company’s mission is to become a leading provider of natural vitamins, minerals and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges. The Company private labels products with key distributors and manufacturing providers.

 

BioForce entered into the supplement business in or about 2015. These supplements, powders and beverages offer vitamins and minerals to complement a healthy intake of protein and carbohydrates for active individuals and participants in sports.

 

BioForce recently changed its business plan and it is in the process of establishing a dynamic marketing campaign to achieve brand awareness of its product offerings to drive business growth through sales of nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online. BioForce currently markets its products through social media and telemarketing. The Company plans to expand marketing efforts with a direct marketing and B2B (Business to Business) sales campaign, with the eventual expectation to expand throughout the entire United States.

 

The Company proactively seeks to expand its “BioForce Eclipse” nutritional powder for use into households throughout the U.S., and the Company will approach retail stores, including health food and sporting goods stores to create a vendor relationship. During this phase, the Company will continue to try to advance its social media platform with direct online and targeted advertisements to health conscience individuals.

 

 -10- 

 

 

Nutrition retailers, grocery stores, retail pharmacies, and online stores, like Amazon, will be important channels for the Company’s Eclipse product-lines. In The USA, there are thousands of direct outlets like grocery stores, pharmacies, hospitals, department stores, medical clinics, surgery clinics, universities, nursing homes, prisons, and other facilities which are all targets of potential sales of the vitamin and mineral supplemental products.

 

BioForce Nanosciences Holdings, Inc. sells the BioForce Eclipse powder multivitamin and mineral supplement without non-compete and non-disclosure agreements. The Company currently private labels the powder through a manufacturer located in Virginia. The Company has a Supplier Agreement with this manufacturer that gives the Company non-exclusion rights to market the product. The distributor owns the rights to the formula for this product. If the Company can source product in a more cost-effective way without diminished quality, the Company would evaluate such opportunities when presented. Currently, the distributor who provides the private label powder provides “Consignment Terms,” which allows us to only pay for the product when it is sold. 

 

The FDA has rules regarding the fitness for consumption of foods as well as vitamins and supplements sold to the public, and those laws apply to our product. However, our product does not require pre-clearance like a drug in order to be sold into the marketplace.

 

The Company in May 2020, formed a wholly-owned subsidiary, Element Acquisition Corporation, a Wyoming corporation,with unlimited common shares authorized, par value $0.001. Element Acquisition Corporation was formed to pursue potential acquisitions in the media, entertainment, media technology and sports sectors.

 

The Company on October 15, 2020 changed the name of its wholly-owned subsidiary Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc., a Wyoming corporation. Management intends to redomicile BioForce Nanosciences Holdings, Inc., a Nevada corporation, into a Wyoming corporation using its wholly-owned BioForce Nanosciences Holdings, Inc., a Wyoming corporation as the entity for the redomicile corporate action.

 

On December 14, 2021, the Company changed the name of its wholly-owned subsidiary, BioForce Nanosciences Holdings, Inc., a Wyoming corporation, to its new name, Element Global, Inc.

 

Memorandum of Understanding ("MOU")

 

September 02, 2021, Bioforce Nanosciences Holdings, Inc. entered into another Memorandum of Understanding (MOU) with Element Global, Inc. (ELGL), a Utah Corporation. This MOU contemplates a proposed transaction between the entities that provides for BFNH to acquire all of the assets controlled by ELGL. The closing of the transaction is subject to due diligence and the execution of a definitive agreement. As of the date of this filing the MOU is still active.

 

Business Advisory Committee

 

The Company's Business Advisory Committee ("Committee") comprised of leading executives with extensive experience in the media, entertainment and sports sectors. The Committee was established to oversee a strategy aimed at acquiring and investing in companies across these industries.

 

The Committee members are the following individuals:

 

- Mark Greenberg is CEO of Element Media Group Inc., and Director of Element Global, Inc. (OTC: ELGL). He served as the Founder and Chief Executive Officer of EPIX from 2009 to 2017 and was previously Executive Vice President for Showtime Networks, Inc., and Director of Direct Marketing at HBO (Home Box Office).

 

- Neil Davis is the Chief Business Development Officer in Element Media Group. Mr. Davis is a seasoned digital executive who has created well over $2 billion of revenue for various companies including, AOL, Blockbuster, Dish Network and Qello Media, where he served as Chief Business Officer. He was previously CEO at Monetize, where he consulted for the media and entertainment industries. Prior to that, he was Head of Corporate and Digital Development at Blockbuster-Dish Digital. 

 

- Stephen Scheffer has served almost 30 years at HBO (Home Box Office) as President of Film Programming, Video and Enterprises. Mr. Scheffer was responsible for overseeing all motion picture programming for HBO. As President of HBO Pictures, he was responsible for the financing and production of HBO’s Silver Screen Partners and Cinema Plus theatrical movie ventures. Prior to HBO, Mr. Scheffer held executive positions at Time Life Films, Allied Artists, Polydor Records, MGM and Columbia Pictures.

 

 -11- 

 

 

Transfer Agent

 

Our transfer agent is Transfer Online, Inc. whose address is 512 SE Salmon Street, Portland, Oregon 97214, and telephone number (503) 227-2950.

 

Company Contact Information

 

Our principal executive and subsidiary offices are located at 2020 General Booth Blvd., Unit 230, Virginia Beach, VA 23454, telephone (757) 306-6090. The information to be contained in our Internet website, www.bioforceeclipse.com, shall not constitute part of this report. 

 

Current Directors

 

The following table provides information concerning our officers and directors. All directors hold office until the next annual meeting of stockholders or until their successors have been elected and qualified.

 

Merle Ferguson Director
Richard Kaiser Director/CFO/Secretary
   
Steve Gagnon Co-CEO
John LaViolette Co-CEO
Sasha Shapiro President

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overall Operating Results:

 

Three Months – September 30, 2024 and 2023 Statements

 

The Sales Revenue from the Company’s BioForce Eclipse vitamin supplements for the three months ended September 30, 2024 and for the three months ended September 30, 2023 were $-0- and $-0-, respectively. During the three months ended September 30, 2024 and 2023 the Company received no orders, -0- units of its Bioforce Eclipse supplement product.

 

The Cost of Goods Sold for the three months ended September 30, 2024 and 2023 was $-0- .

 

Gross Margins for the three months ended September 30, 2024 and 2023 was 0% from the sale of -0- units of the BioForce Eclipse supplement product.

 

Gross Profit for the three months ended September 30, 2024 and 2023 was $-0- .

 

Operating expenses for three months ended September 30, 2024 totaled 122,024 from Board of Director compensation and General and Administrative Expenses, compared to $113,607 for the three months ended September 30, 2023. The increase in the three months ended September 30, 2024 compared to the same period ended September 30, 2023 was attributed to higher expenses from professional services rendered.

 

Nine Months – September 30, 2024 and 2023 Statements

 

The Sales Revenue from the Company’s "BioForce Eclipse" vitamin supplement for the nine months ended September 30, 2024 and 2023 were $-0-, Company sold no units of its Bioforce Eclipse" vitamin supplement.

 

The Cost of Sales for the nine months ended September 30, 2024 and 2023 were $-0-.

 

Gross Margins for the nine months ended September 30, 2024 and 2023 were 0% from the sale of -0- units of the “BioForce Eclipse” supplement product.

 

Gross Profit for the six months ended September 30, 2024 and 2023 were $-0-.

 

Operating expenses for nine months ended September 30, 2024, totaled $367,277 for Board of Director Compensation and General and Administrative Expenses, compared to $357,543 for the nine months ended September 30, 2023. The increase in the nine months ended September 30, 2024 compared to the same period ended September 30, 2023 was attributed to higher expenses from professional services rendered.

 

 -12- 

 

 

Net Loss:

 

Net loss for the three months ended September 30, 2024 and 2023 were $122,024 and $113,607 respectively. Net loss for the nine months ended September 30, 2024 and 2023 were $367,277 and $357,543 , respectively.

 

Liquidity and Capital Resources:

 

As of September 30, 2024, the Company’s assets totaled $1,635, which consisted of cash. Our total liabilities were $2,180,067 from accounts payable and accrued expenses, accrued director compensation expenses and amounts due to related parties. As of September 30, 2024, the Company had an accumulated deficit of $160,997,006 and working capital deficit $2,178,432.

 

As indicated herein, we need capital for the implementation of our business plan, and we will need additional capital for continuing our operations. We do not have sufficient revenues to pay our operating expenses at this time. Unless the company is able to raise working capital, it is likely that the Company will either have to cease operations or substantially change its methods of operations or change its business plan (See Note 4 in Financial Statements). For the next 12 months the Company has a written commitment from its Chairman Mr. Merle Ferguson's to advance funds as necessary in meeting the Company's operating requirements.

 

BioForce NanoSciences Holdings, Inc. does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company, or any of its subsidiaries’ operating results, financial position, or cash flow.

 

Cash Provided by (Used in) Operating Activities

 

Net cash used in operating activities for the nine months ended September 30, 2024 and 2023 were $46,415 and $39,616, respectively.

 

Cash Flows from Investing Activities

 

Net cash used in investing activities was $-0- for both the nine month periods ended September 30, 2024 and 2023.

 

Cash Provided by Financing Activities

 

Net cash provided by financing activities was $47,412 for nine months ended September 30, 2024 from capital contributions and proceeds from related parties, and was $39,568 for nine months ended September 30, 2023 from proceeds from Related Parties.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

New Accounting Pronouncements

 

BioForce Nanosciences Holdings, Inc. does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company, or any of its subsidiaries' operating results, financial position, or cash flow.

 

Accounting Principals

 

Our consolidated financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. Critical accounting policies include revenue recognition and impairment of long-lived assets.

 

 -13- 

 

 

Revenue Recognition

 

In accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), revenues are recognized when control of the promised goods or services is transferred to our clients, in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the company satisfies a performance obligation.

 

We adopted this ASU on January 1, 2018. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities within them.

 

Share Structure

 

We were authorized to issue 900,000,000 shares of our common stock, of which 29,271,755 shares are outstanding. Our shares of common stock are held by approximately 235 stockholders of record. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our common stock whose shares are held in the names of various securities brokers, dealers, and registered clearing agencies. In addition to our authorized common stock, BioForce Nanosciences Holdings, Inc. is authorized to issue 100,000,000 shares of preferred stock, par value at $0.001 per share. Based on the amended Articles of Incorporation the Company has 10,000,000 Series 'A' Preferred which have voting and conversion rights of 100 common shares, par value $0.001; leaving a balance of 90,000,000 "Blank Check" Preferred. There are no Series 'A' Preferred shares issued or outstanding.

 

Going Concern

 

We have incurred net losses since our inception. We anticipate incurring additional losses before realizing growth in revenue and we will depend on additional financing in order to meet our continuing obligations and ultimately to attain profitability. Our ability to obtain additional financing, whether through the issuance of additional equity or through the assumption of debt, is uncertain. Accordingly, our independent auditors' report on our financial statements for the year ended December 31, 2023 includes an explanatory paragraph regarding concerns about our ability to continue as a going concern, including additional information contained in the notes to our financial statements describing the circumstances leading to this disclosure. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue our business.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. 

 

Based on our evaluation, our Principal Executive Officer and Principal Financial Officer, after considering the existence of material weaknesses identified, determined that our internal control over financial reporting disclosure controls and procedures were not effective as of September 30, 2024.

 

Evaluation of Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

 

 -14- 

 

 

Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with the authorization of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management, including our Principal Executive Officer and Principal Financial Officer, assessed the effectiveness of our internal control over financial reporting as of September 30, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control – Integrated Framework (2013).

 

We identified the following deficiencies which together constitute a material weakness in our assessment of the effectiveness of internal control over financial reporting as of September 30, 2024: 

 

  - The Company has inadequate segregation of duties within its cash disbursement control design.
     
  - During the period ended September 30, 2024, the Company internally performed all aspects of its financial reporting process, including, but not limited to the underlying accounting records and the recording of journal entries and for the preparation of financial statements. This process was deficient, because these duties were performed often times by the same people, and therefore a lack of review was created over the financial reporting process that might result in a failure to detect errors in spreadsheets, calculations, or assumptions used to compile the financial statements and related disclosures as filed with the SEC. These control deficiencies could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected.

 

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control system, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

This report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management's report in this annual report.

 

We regularly review our system of internal control over financial reporting to ensure that we maintain an effective internal control environment. If deficiencies appear in our internal controls, management will make changes that address those deficiencies.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in the Company's internal control over financial reporting that occurred during the reporeting period ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

At this time, there are no materials pending legal proceedings to which the Company is a party or as to which any of its property and products are subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

 -15- 

 

 

ITEM 4. MINING SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None

 

ITEM 6. EXHIBITS

 

Index to Exhibits.

 

Exhibit No.   Description of Exhibit
31.1   Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.+
     
31.2   Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.+
     
32.1   Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.+
     
32.2   Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.+
     
101   Interactive Financial Data XBRL Extensions+
      
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)+

 

+ filed herewith

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the Registrant caused this Amended report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BIOFORCE NANOSCIENCES HOLDINGS, INC.

 

Dated: November 8, 2024 By: /s/Steve Gagnon  
 

Steve Gagnon

Chief Executive Officer

 
       
  By: /s/Richard Kaiser  
 

Richard Kaiser

Chief Financial Officer, Principal Accounting Officer and Secretary

 

 

 -16- 

 

EX-31.1 2 ex311.htm CHIEF EXECUTIVE OFFICER CERTIFICATION

Exhibit 31.1

CHIEF EXECUTIVE OFFICER

I, Steve Gagnon, hereby certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Bioforce Nanosciences Holdings, Inc..;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

  

Dated: November 8, 2024

/s/Steve Gagnon

Steve Gagnon

Chief Executive Officer

EX-31.2 3 ex312.htm CHIEF FINANCIAL OFFICER CERTIFICATION

Exhibit 31.2

CHIEF FINANCIAL OFFICER

I, Richard Kaiser, hereby certify that:

(1) I have reviewed this quarterly report on Form 10-Q of BioForce Nanosciences Holdings, Inc..;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

  

 

 

Dated: November 8, 2024

/s/Richard Kaiser

Richard Kaiser

Chief  Financial Officer

 


EX-32.1 4 ex321.htm CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officers of  Bioforce Nanosciences Holdings, Inc., a Nevada corporation (the "Company"), do hereby certify, to the best of their knowledge, that:

 

1.     The Quarterly Report on Form 10-Q for the period ending September 30, 2024 (the "Report") of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  

 

Dated:  November 8, 2024

/s/Steve Gagnon

Steve Gagon

Chief Executive Officer

 

EX-32.2 5 ex322.htm CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.2

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officers of Bioforce Nanosciences Holdings, Inc., a Nevada corporation (the "Company"), do hereby certify, to the best of their knowledge, that:

 

1.     The Quarterly Report on Form 10-Q for the period ending September 30, 2024 (the "Report") of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  

 

Dated: November 8, 2024

/s/Richard Kaiser

Richard Kaiser

Chief Financial Officer

 

EX-101.SCH 6 bfnh-20240930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT UNAUDITED link:presentationLink link:calculationLink link:definitionLink 995612 - Disclosure - Organization & Description of Business link:presentationLink link:calculationLink link:definitionLink 995613 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995614 - Disclosure - Recently Issued Accounting Standards link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 995616 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995617 - Disclosure - Stock link:presentationLink link:calculationLink link:definitionLink 995618 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995619 - Disclosure - Organization & Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995620 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995621 - Disclosure - Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bfnh-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bfnh-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bfnh-20240930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets Cash Total Current Assets Total Assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts Payable and Accrued Expenses Accrued Board of Directors Compensation Due to Related Parties Total Current Liabilities Total Liabilities Stockholders' Deficit Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 29,271,755 Issued and Outstanding, Respectively Additional Paid-In-Capital Accumulated Deficit Total Stockholders' Deficit Total Liabilities and Stockholders' Deficit Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sales Cost of Sales Gross Profit Operating Expenses Board of Directors Compensation General and Administrative Total Expenses Net Loss for the Period Weighted Average Number of Common Shares - Basic Weighted Average Number of Common Shares - Diluted Net Loss for the Period Per Common Shares - Basic Net Loss for the Period Per Common Shares - Diluted Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net Loss for the Period Changes in Assets and Liabilities: Accounts Payable and Accrued Expenses Accrued Board of Directors Compensation Net Cash Flows Used In Operating Activities Cash Flows from Investing Activities Cash Flows from Financing Activities Captial Contributions Proceeds from Related Parties Net Cash Flows Provided by Financing Activities Net Change in Cash Cash - Beginning of Period Cash - End of Period Cash Paid During the Period for: Interest Income Taxes Statement [Table] Statement [Line Items] Balance - June 30, 2024 Beginning balance, shares Captial Contributions Net Loss for the Period Balance - September 30, 2024 Ending balance, shares Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Type [Axis] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] Organization & Description of Business Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] Recently Issued Accounting Standards Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Related Party Transactions [Abstract] Related Party Transactions Equity [Abstract] Stock Basis of Presentation Principles of Consolidation Use of Estimates Earnings (Loss) per Share Stock-Based Compensation Fair Value of Financial Instruments Revenue Recognition Number of shares purchased Payment to acquire subsidiary Expenses Due to related parties Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock, shares authorized Preferred stock, par value Preferred stock conversion basis Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par or stated value per share Reverse stock split Common stock, shares, issued Common stock, shares, outstanding Business Acquisition Equity Interests Purchased Number Of Shares. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses [Default Label] Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accrued Salaries Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Shares, Outstanding Stock Issued During Period, Value, Conversion of Units Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name EX-101.PRE 10 bfnh-20240930_pre.xml XBRL PRESENTATION FILE GRAPHIC 11 bfnhlogo2019001.jpg GRAPHIC begin 644 bfnhlogo2019001.jpg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htm IDEA: XBRL DOCUMENT v3.24.3
Cover - shares
9 Months Ended
Sep. 30, 2024
Nov. 07, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2024  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 000-51074  
Entity Registrant Name BIOFORCE NANOSCIENCES HOLDINGS, INC.  
Entity Central Index Key 0001310488  
Entity Tax Identification Number 74-3078125  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 2020 General Booth Blvd.  
Entity Address, Address Line Two Unit 230  
Entity Address, City or Town Virginia Beach  
Entity Address, State or Province VA  
Entity Address, Postal Zip Code 23454  
City Area Code 757  
Local Phone Number 306-6090  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   29,271,755
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Current Assets    
Cash $ 1,635 $ 638
Total Current Assets 1,635 638
Total Assets 1,635 638
Current Liabilities    
Accounts Payable and Accrued Expenses 6,261 2,649
Accrued Board of Directors Compensation 1,913,767 1,596,517
Due to Related Parties 260,039 220,702
Total Current Liabilities 2,180,067 1,819,868
Total Liabilities 2,180,067 1,819,868
Stockholders' Deficit    
Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 29,271,755 Issued and Outstanding, Respectively 29,272 29,272
Additional Paid-In-Capital 158,789,302 158,781,227
Accumulated Deficit (160,997,006) (160,629,729)
Total Stockholders' Deficit (2,178,432) (1,819,230)
Total Liabilities and Stockholders' Deficit $ 1,635 $ 638
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized 900,000,000 900,000,000
Common stock, shares issued 29,271,755 29,271,755
Common stock, shares outstanding 29,271,755 29,271,755
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Sales
Cost of Sales
Gross Profit
Operating Expenses        
Board of Directors Compensation 105,750 105,750 317,250 317,250
General and Administrative 16,274 7,857 50,027 40,293
Total Expenses 122,024 113,607 367,277 357,543
Net Loss for the Period $ (122,024) $ (113,607) $ (367,277) $ (357,543)
Weighted Average Number of Common Shares - Basic 29,271,755 29,271,755 29,271,755 29,271,755
Weighted Average Number of Common Shares - Diluted 29,271,755 29,271,755 29,271,755 29,271,755
Net Loss for the Period Per Common Shares - Basic $ (0.00) $ (0.00) $ (0.01) $ (0.01)
Net Loss for the Period Per Common Shares - Diluted $ (0.00) $ (0.00) $ (0.01) $ (0.01)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED - USD ($)
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash Flows from Operating Activities    
Net Loss for the Period $ (367,277) $ (357,543)
Changes in Assets and Liabilities:    
Accounts Payable and Accrued Expenses 3,612 677
Accrued Board of Directors Compensation 317,250 317,250
Net Cash Flows Used In Operating Activities (46,415) (39,616)
Cash Flows from Investing Activities
Cash Flows from Financing Activities    
Captial Contributions 8,075
Proceeds from Related Parties 39,337 39,568
Net Cash Flows Provided by Financing Activities 47,412 39,568
Net Change in Cash 997 (48)
Cash - Beginning of Period 638 734
Cash - End of Period 1,635 686
Cash Paid During the Period for:    
Interest
Income Taxes
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT UNAUDITED - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance - June 30, 2024 at Dec. 31, 2022 $ 29,272 $ 158,781,227 $ (160,157,776) $ (1,347,277)
Beginning balance, shares at Dec. 31, 2022 29,271,755      
Net Loss for the Period (130,005) (130,005)
Balance - September 30, 2024 at Mar. 31, 2023 $ 29,272 158,781,227 (160,287,781) (1,477,282)
Ending balance, shares at Mar. 31, 2023 29,271,755      
Net Loss for the Period (113,931) (113,931)
Balance - September 30, 2024 at Jun. 30, 2023 $ 29,272 158,781,227 (160,401,712) (1,591,213)
Ending balance, shares at Jun. 30, 2023 29,271,755      
Net Loss for the Period (113,607) (113,607)
Balance - September 30, 2024 at Sep. 30, 2023 $ 29,272 158,781,227 (160,515,319) (1,704,820)
Ending balance, shares at Sep. 30, 2023 29,271,755      
Balance - June 30, 2024 at Dec. 31, 2023 $ 29,272 158,781,227 (160,629,729) (1,819,230)
Beginning balance, shares at Dec. 31, 2023 29,271,755      
Net Loss for the Period (130,813) (130,813)
Balance - September 30, 2024 at Mar. 31, 2024 $ 29,272 158,781,227 (160,760,542) (1,950,043)
Ending balance, shares at Mar. 31, 2024 29,271,755      
Captial Contributions 75 75
Net Loss for the Period (114,440) (114,440)
Balance - September 30, 2024 at Jun. 30, 2024 $ 29,272 158,781,302 (160,874,982) (2,064,408)
Ending balance, shares at Jun. 30, 2024 29,271,755      
Captial Contributions 8,000 8,000
Net Loss for the Period (122,024) (122,024)
Balance - September 30, 2024 at Sep. 30, 2024 $ 29,272 $ 158,789,302 $ (160,997,006) $ (2,178,432)
Ending balance, shares at Sep. 30, 2024 29,271,755      
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure [Table]        
Net Income (Loss) $ (122,024) $ (113,607) $ (367,277) $ (357,543)
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
9 Months Ended
Sep. 30, 2024
Insider Trading Arrangements [Line Items]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Organization & Description of Business
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Organization & Description of Business

NOTE 1 – Organization & Description of Business

 

The Company was incorporated in the State of Nevada on December 10, 1999 as Silver River Ventures, Inc. On February 24, 2006, the Company completed the acquisition of BioForce Nanosciences Holdings Inc. (“BioForce”), a Delaware corporation, and changed the corporate name at that time. On May 6, 2020, the Company purchased 100,000 shares of Element Acquisition Corporation for $1,000 which then became a wholly owned subsidiary. On October 15, 2020, the Company’s wholly-owned subsidiary changed its name from Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc, a Wyoming corporation. On December 14, 2021, the Company’s wholly-owned subsidiary changed its name from BioForce Nanosciences Holdings, Inc., a Wyoming corporation to Element Global Inc., a Wyoming corporation. The Company’s mission is to become a leading provider of vitamin, mineral and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges.

 

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

NOTE 2 – Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed consolidated balance sheet has been derived from the December 31, 2023 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2024 and 2023, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results of operations expected for the year ending December 31, 2024.

 

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Earnings (Loss) per Share

 

Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share.

 

Stock-Based Compensation 

 

We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation—Stock Compensation, which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values.  The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.

 

Fair Value of Financial Instruments

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates.

Revenue Recognition

 

The Company implemented ASC 606, Revenue from Contracts with Customers. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.

 

The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.

 

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Recently Issued Accounting Standards
9 Months Ended
Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Standards

NOTE 3 – Recently Issued Accounting Standards

 

The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements, including the new lease standard. The Company does not have any leases and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Going Concern
9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

NOTE 4 – Going Concern 

 

The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has reported recurring losses from operations and has net current liabilities and an accumulated deficit. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.

 

While the Company is attempting to continue operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management believes that the actions presently being taken to further implement the Company’s business plan; to expand sales with a dynamic marketing campaign and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. During the nine months ended September 30, 2023 due to lack of revenues the officers of the Company paid for all expenses through loans to the Company. This allowed the Company to continue as a going concern.

 

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Related Party Transactions
9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
Related Party Transactions

NOTE 5 – Related Party Transactions

 

The Company’s Director, Secretary and Acting CFO, Richard Kaiser, is the operator of Yes International, a full-service investor relations firm. He handles duties of the Company regarding his officer capacities as the Secretary and Acting CFO, but also provides investor relations services through Yes International for the Company at no charge.

 

During the nine months ended September 30, 2024 and 2023, two board of directors paid expenses of the Company in the amount of $39,338 and $39,568, respectively. Due to related parties was $260,039 and $213,664 at September 30, 2024 and 2023, respectively.

 

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Stock
9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Stock

NOTE 6 – Stock

 

Preferred Stock

 

Preferred stock consists of 100,000,000 shares authorized at $0.001 par value. 10,000,000 of these preferred shares have been separately allocated to Series A Preferred. Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock. At September 30, 2024 and December 31, 2023, there were -0- Series A Preferred shares issued and outstanding.

 

Common Stock

 

Common stock consists of 900,000,000 shares authorized at $0.001 par value. On November 25, 2019, the board of directors approved a 5 to 1 reverse split. At September 30, 2024 and December 31, 2023, there were 29,271,755 shares issued and outstanding, respectively.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying condensed consolidated balance sheet has been derived from the December 31, 2023 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2024 and 2023, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results of operations expected for the year ending December 31, 2024.

 

Principles of Consolidation

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Earnings (Loss) per Share

Earnings (Loss) per Share

 

Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share.

 

Stock-Based Compensation

Stock-Based Compensation 

 

We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation—Stock Compensation, which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values.  The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates.

Revenue Recognition

Revenue Recognition

 

The Company implemented ASC 606, Revenue from Contracts with Customers. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.

 

The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.

 

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Organization & Description of Business (Details Narrative)
May 06, 2020
USD ($)
shares
Accounting Policies [Abstract]  
Number of shares purchased | shares 100,000
Payment to acquire subsidiary | $ $ 1,000
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Related Party Transactions (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Related Party Transactions [Abstract]      
Expenses $ 39,338 $ 39,568  
Due to related parties $ 260,039 $ 213,664 $ 220,702
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Stock (Details Narrative) - $ / shares
1 Months Ended 9 Months Ended
Nov. 25, 2019
Sep. 30, 2024
Dec. 31, 2023
Class of Stock [Line Items]      
Preferred stock, shares authorized   100,000,000 100,000,000
Preferred stock, par value   $ 0.001 $ 0.001
Preferred stock conversion basis   Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock.  
Common stock, shares authorized   900,000,000 900,000,000
Common stock, par or stated value per share   $ 0.001 $ 0.001
Reverse stock split 5 to 1 reverse split.    
Common stock, shares, issued   29,271,755 29,271,755
Common stock, shares, outstanding   29,271,755 29,271,755
Series A Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, shares authorized   10,000,000 10,000,000
Preferred stock, shares issued   0 0
Preferred stock, shares outstanding   0 0
EXCEL 31 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 63 95 1 false 4 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioforcenano.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED Sheet http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (Parenthetical) Sheet http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-UnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED Sheet http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED Sheet http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT UNAUDITED Sheet http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT UNAUDITED Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995612 - Disclosure - Organization & Description of Business Sheet http://bioforcenano.com/role/OrganizationDescriptionOfBusiness Organization & Description of Business Notes 9 false false R10.htm 995613 - Disclosure - Summary of Significant Accounting Policies Sheet http://bioforcenano.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995614 - Disclosure - Recently Issued Accounting Standards Sheet http://bioforcenano.com/role/RecentlyIssuedAccountingStandards Recently Issued Accounting Standards Notes 11 false false R12.htm 995615 - Disclosure - Going Concern Sheet http://bioforcenano.com/role/GoingConcern Going Concern Notes 12 false false R13.htm 995616 - Disclosure - Related Party Transactions Sheet http://bioforcenano.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 995617 - Disclosure - Stock Sheet http://bioforcenano.com/role/Stock Stock Notes 14 false false R15.htm 995618 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://bioforcenano.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 995619 - Disclosure - Organization & Description of Business (Details Narrative) Sheet http://bioforcenano.com/role/OrganizationDescriptionOfBusinessDetailsNarrative Organization & Description of Business (Details Narrative) Details http://bioforcenano.com/role/OrganizationDescriptionOfBusiness 16 false false R17.htm 995620 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://bioforcenano.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://bioforcenano.com/role/RelatedPartyTransactions 17 false false R18.htm 995621 - Disclosure - Stock (Details Narrative) Sheet http://bioforcenano.com/role/StockDetailsNarrative Stock (Details Narrative) Details http://bioforcenano.com/role/Stock 18 false false All Reports Book All Reports bfnh-20240930.xsd bfnh-20240930_cal.xml bfnh-20240930_def.xml bfnh-20240930_lab.xml bfnh-20240930_pre.xml bfnh20240930_10q.htm bfnhlogo2019001.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 37 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bfnh20240930_10q.htm": { "nsprefix": "bfnh", "nsuri": "http://bioforcenano.com/20240930", "dts": { "schema": { "local": [ "bfnh-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bfnh-20240930_cal.xml" ] }, "definitionLink": { "local": [ "bfnh-20240930_def.xml" ] }, "labelLink": { "local": [ "bfnh-20240930_lab.xml" ] }, "presentationLink": { "local": [ "bfnh-20240930_pre.xml" ] }, "inline": { "local": [ "bfnh20240930_10q.htm" ] } }, "keyStandard": 92, "keyCustom": 3, "axisStandard": 2, "axisCustom": 0, "memberStandard": 4, "memberCustom": 0, "hidden": { "total": 40, "http://fasb.org/us-gaap/2024": 34, "http://xbrl.sec.gov/dei/2024": 5, "http://bioforcenano.com/20240930": 1 }, "contextCount": 63, "entityCount": 1, "segmentCount": 4, "elementCount": 239, "unitCount": 3, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 208, "http://xbrl.sec.gov/dei/2024": 27, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://bioforcenano.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-UnauditedParenthetical", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "unique": true } }, "R6": { "role": "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT UNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT UNAUDITED", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://bioforcenano.com/role/OrganizationDescriptionOfBusiness", "longName": "995612 - Disclosure - Organization & Description of Business", "shortName": "Organization & Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://bioforcenano.com/role/SummaryOfSignificantAccountingPolicies", "longName": "995613 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://bioforcenano.com/role/RecentlyIssuedAccountingStandards", "longName": "995614 - Disclosure - Recently Issued Accounting Standards", "shortName": "Recently Issued Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://bioforcenano.com/role/GoingConcern", "longName": "995615 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://bioforcenano.com/role/RelatedPartyTransactions", "longName": "995616 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://bioforcenano.com/role/Stock", "longName": "995617 - Disclosure - Stock", "shortName": "Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995618 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://bioforcenano.com/role/OrganizationDescriptionOfBusinessDetailsNarrative", "longName": "995619 - Disclosure - Organization & Description of Business (Details Narrative)", "shortName": "Organization & Description of Business (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "16", "firstAnchor": { "contextRef": "From2020-05-012020-05-06", "name": "bfnh:BusinessAcquisitionEquityInterestsPurchasedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2020-05-012020-05-06", "name": "bfnh:BusinessAcquisitionEquityInterestsPurchasedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://bioforcenano.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995620 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OtherExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OtherExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://bioforcenano.com/role/StockDetailsNarrative", "longName": "995621 - Disclosure - Stock (Details Narrative)", "shortName": "Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bfnh20240930_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r23", "r24" ] }, "us-gaap_AccruedSalariesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Accrued Board of Directors Compensation", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided." } } }, "auth_ref": [ "r55" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r442" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In-Capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r299", "r490", "r491", "r492", "r493", "r504", "r509" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r448" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r448" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r448" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r448" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r413", "r424", "r434", "r459" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r416", "r427", "r437", "r462" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r448" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r455" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r417", "r428", "r438", "r455", "r463", "r467", "r475" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r420" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r54", "r61", "r75", "r96", "r127", "r131", "r135", "r136", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r231", "r235", "r249", "r273", "r330", "r378", "r379", "r383", "r394", "r501", "r502", "r506" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r72", "r79", "r96", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r231", "r235", "r249", "r383", "r501", "r502", "r506" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r420" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r470" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r471" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r466" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r466" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r466" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r466" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r466" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r466" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r209", "r210", "r211" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r469" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r468" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r467" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r467" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "bfnh_BusinessAcquisitionEquityInterestsPurchasedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://bioforcenano.com/20240930", "localname": "BusinessAcquisitionEquityInterestsPurchasedNumberOfShares", "presentation": [ "http://bioforcenano.com/role/OrganizationDescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares purchased", "documentation": "Business Acquisition Equity Interests Purchased Number Of Shares." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://bioforcenano.com/role/OrganizationDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization & Description of Business", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r21", "r45", "r46" ] }, "bfnh_CaptialContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://bioforcenano.com/20240930", "localname": "CaptialContributions", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Captial Contributions" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r7", "r74", "r373" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash - Beginning of Period", "periodEndLabel": "Cash - End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r7", "r42", "r93" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Change in Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r42" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r446" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r68", "r76", "r77", "r78", "r96", "r119", "r120", "r122", "r124", "r129", "r130", "r142", "r148", "r150", "r151", "r152", "r155", "r156", "r158", "r159", "r162", "r165", "r172", "r249", "r290", "r291", "r292", "r293", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r318", "r339", "r359", "r366", "r367", "r368", "r369", "r370", "r483", "r488", "r494" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r76", "r77", "r78", "r129", "r158", "r159", "r160", "r162", "r165", "r170", "r172", "r290", "r291", "r292", "r293", "r380", "r483", "r488" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r447" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r447" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r384", "r385", "r386", "r388", "r389", "r390", "r391", "r490", "r491", "r493", "r504", "r508", "r509" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-UnauditedParenthetical", "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value per share", "verboseLabel": "Common stock, par or stated value per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r31" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-UnauditedParenthetical", "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r31", "r318" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-UnauditedParenthetical", "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "verboseLabel": "Common stock, shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r31" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-UnauditedParenthetical", "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "verboseLabel": "Common stock, shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r3", "r31", "r318", "r336", "r509", "r510" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 29,271,755 Issued and Outstanding, Respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r31", "r274", "r383" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r452" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r451" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r453" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r450" ] }, "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Board of Directors Compensation", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold." } } }, "auth_ref": [ "r378", "r487" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r20", "r374" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Cost of Sales", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r38", "r96", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r249", "r378", "r501" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r408" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r406", "r408", "r420" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r407" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r395" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r408" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r408" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r441" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r398" ] }, "bfnh_DueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://bioforcenano.com/20240930", "localname": "DueToRelatedParties", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited", "http://bioforcenano.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due to Related Parties", "verboseLabel": "Due to related parties" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Net Loss for the Period Per Common Shares - Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r86", "r106", "r107", "r108", "r109", "r110", "r111", "r117", "r119", "r122", "r123", "r124", "r126", "r225", "r229", "r247", "r248", "r271", "r280", "r375" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Net Loss for the Period Per Common Shares - Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r86", "r106", "r107", "r108", "r109", "r110", "r111", "r119", "r122", "r123", "r124", "r126", "r225", "r229", "r247", "r248", "r271", "r280", "r375" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings (Loss) per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r9", "r10", "r125" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r401" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r397" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r397" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r482" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r397" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r479" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r420" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r397" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r397" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r397" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r397" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r480" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r3", "r69", "r82", "r83", "r84", "r97", "r98", "r99", "r103", "r110", "r112", "r114", "r128", "r143", "r146", "r147", "r173", "r218", "r219", "r220", "r221", "r222", "r226", "r228", "r229", "r237", "r238", "r239", "r240", "r241", "r243", "r246", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r279", "r281", "r282", "r283", "r299", "r359" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r449" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r413", "r424", "r434", "r459" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r410", "r421", "r431", "r456" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r455" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r2" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r417", "r428", "r438", "r463" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r417", "r428", "r438", "r463" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r417", "r428", "r438", "r463" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r417", "r428", "r438", "r463" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r417", "r428", "r438", "r463" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "General and Administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r40", "r341" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r37", "r38", "r60", "r96", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r249", "r377", "r378", "r495", "r496", "r497", "r498", "r499", "r501" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r8", "r92", "r216", "r217" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts Payable and Accrued Expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInAccruedSalaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedSalaries", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued Board of Directors Compensation", "label": "Increase (Decrease) in Accrued Salaries", "documentation": "The increase (decrease) during the period in accrued salaries." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Changes in Assets and Liabilities:" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r417", "r428", "r438", "r455", "r463", "r467", "r475" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r473" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r409", "r478" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r409", "r478" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r409", "r478" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r87", "r90", "r91" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r4", "r23", "r24", "r25", "r26", "r27", "r28", "r29", "r96", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r232", "r235", "r236", "r249", "r317", "r376", "r394", "r501", "r506", "r507" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders' Deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r36", "r56", "r276", "r383", "r489", "r500", "r505" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r25", "r73", "r96", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r232", "r235", "r236", "r249", "r383", "r501", "r506", "r507" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r447" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r447" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r466" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r474" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r448" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows Provided by Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r89" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r89" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows Used In Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited", "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss for the Period", "label": "Net Loss for the Period", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r39", "r44", "r57", "r71", "r80", "r81", "r84", "r96", "r102", "r106", "r107", "r108", "r109", "r110", "r113", "r114", "r121", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r225", "r229", "r248", "r249", "r278", "r338", "r357", "r358", "r392", "r501" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://bioforcenano.com/role/RecentlyIssuedAccountingStandards" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r66", "r70", "r100", "r101", "r104", "r105", "r115", "r116", "r140", "r144", "r145", "r223", "r224", "r226", "r229", "r242", "r245", "r258", "r260", "r261", "r268", "r269", "r270", "r284", "r285", "r286", "r287", "r288" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r447" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r445" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r444" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r474" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r474" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Expenses", "label": "Operating Expenses [Default Label]", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://bioforcenano.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r40", "r41" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r447" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r408" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r415", "r426", "r436", "r461" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r418", "r429", "r439", "r464" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r418", "r429", "r439", "r464" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r443" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://bioforcenano.com/role/OrganizationDescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment to acquire subsidiary", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r5", "r227" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r446" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r446" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r445" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r448" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r444" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r445" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r402" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r404" ] }, "us-gaap_PreferredStockConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConversionBasis", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock conversion basis", "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted." } } }, "auth_ref": [ "r16", "r30" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r30", "r158" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r30", "r318" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r30", "r158" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r30", "r318", "r336", "r509", "r510" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from Related Parties", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net Loss for the Period", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r71", "r80", "r81", "r88", "r96", "r102", "r110", "r113", "r114", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r225", "r229", "r230", "r233", "r234", "r248", "r249", "r272", "r277", "r298", "r338", "r357", "r358", "r381", "r382", "r393", "r486", "r501" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r443" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r443" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r410", "r421", "r431", "r456" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://bioforcenano.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r295", "r296", "r297", "r342", "r343", "r344", "r363", "r365" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r411", "r422", "r432", "r457" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r412", "r423", "r433", "r458" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r419", "r430", "r440", "r465" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r33", "r52", "r275", "r284", "r288", "r294", "r319", "r383" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r69", "r97", "r98", "r99", "r103", "r110", "r112", "r114", "r143", "r146", "r147", "r218", "r219", "r220", "r221", "r222", "r226", "r228", "r229", "r237", "r239", "r240", "r243", "r246", "r256", "r257", "r281", "r283", "r299", "r509" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r67", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r372" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Sales", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r58", "r59", "r85", "r96", "r127", "r132", "r133", "r134", "r136", "r137", "r138", "r139", "r142", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r249", "r272", "r378", "r501" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r474" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r474" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r14", "r15", "r16", "r17", "r18", "r19", "r48", "r50", "r51", "r52", "r76", "r77", "r78", "r129", "r158", "r159", "r160", "r162", "r165", "r170", "r172", "r290", "r291", "r292", "r293", "r380", "r483", "r488" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r396" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r400" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r399" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r405" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r484", "r485", "r503" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r209", "r210", "r211" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r182", "r186", "r205", "r206", "r207", "r208", "r211", "r212", "r213", "r214", "r215" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r45", "r94" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r403" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r68", "r76", "r77", "r78", "r96", "r119", "r120", "r122", "r124", "r129", "r130", "r142", "r148", "r150", "r151", "r152", "r155", "r156", "r158", "r159", "r162", "r165", "r172", "r249", "r290", "r291", "r292", "r293", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r318", "r339", "r359", "r366", "r367", "r368", "r369", "r370", "r483", "r488", "r494" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r3", "r31", "r34", "r35", "r69", "r82", "r83", "r84", "r97", "r98", "r99", "r103", "r110", "r112", "r114", "r128", "r143", "r146", "r147", "r173", "r218", "r219", "r220", "r221", "r222", "r226", "r228", "r229", "r237", "r238", "r239", "r240", "r241", "r243", "r246", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r279", "r281", "r282", "r283", "r299", "r359" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r97", "r98", "r99", "r128", "r257", "r267", "r289", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r337", "r340", "r341", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r387" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r97", "r98", "r99", "r128", "r141", "r257", "r267", "r289", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r337", "r340", "r341", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r387" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r414", "r425", "r435", "r460" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Captial Contributions", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r3", "r31", "r34", "r35", "r52" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited", "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders' Deficit", "periodStartLabel": "Balance - June 30, 2024", "periodEndLabel": "Balance - September 30, 2024", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r31", "r34", "r35", "r47", "r320", "r336", "r360", "r361", "r383", "r394", "r489", "r500", "r505", "r509" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedBalanceSheets-Unaudited" ], "lang": { "en-us": { "role": { "label": "Stockholders' Deficit" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://bioforcenano.com/role/Stock" ], "lang": { "en-us": { "role": { "label": "Stock", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r49", "r95", "r157", "r159", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r173", "r244", "r362", "r364", "r371" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://bioforcenano.com/role/StockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r53" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://bioforcenano.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r22" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfCashFlows-Unaudited" ], "lang": { "en-us": { "role": { "label": "Cash Paid During the Period for:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r454" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r446" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r453" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r476" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r477" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r477" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r475" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r475" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r476" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r472" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://bioforcenano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r11", "r12", "r13", "r62", "r63", "r64", "r65" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Common Shares - Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r118", "r124" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://bioforcenano.com/role/CondensedConsolidatedStatementsOfOperations-Unaudited" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Common Shares - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r117", "r124" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://bioforcenano.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r481" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r381": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r382": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r383": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r384": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r393": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r394": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r395": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r396": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r397": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r402": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r403": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r404": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r405": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r406": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r407": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r408": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r409": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r410": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r411": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r412": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r413": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r414": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r415": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r416": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r417": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r418": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r419": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r420": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r421": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r422": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r423": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r483": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 38 0001091818-24-000134-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001091818-24-000134-xbrl.zip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end XML 39 bfnh20240930_10q_htm.xml IDEA: XBRL DOCUMENT 0001310488 2024-01-01 2024-09-30 0001310488 2024-11-07 0001310488 2024-09-30 0001310488 2023-12-31 0001310488 2024-07-01 2024-09-30 0001310488 2023-07-01 2023-09-30 0001310488 2023-01-01 2023-09-30 0001310488 2022-12-31 0001310488 2023-09-30 0001310488 us-gaap:CommonStockMember 2022-12-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001310488 us-gaap:RetainedEarningsMember 2022-12-31 0001310488 us-gaap:CommonStockMember 2023-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001310488 us-gaap:RetainedEarningsMember 2023-03-31 0001310488 2023-03-31 0001310488 us-gaap:CommonStockMember 2023-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001310488 us-gaap:RetainedEarningsMember 2023-06-30 0001310488 2023-06-30 0001310488 us-gaap:CommonStockMember 2023-12-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001310488 us-gaap:RetainedEarningsMember 2023-12-31 0001310488 us-gaap:CommonStockMember 2024-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001310488 us-gaap:RetainedEarningsMember 2024-03-31 0001310488 2024-03-31 0001310488 us-gaap:CommonStockMember 2024-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001310488 us-gaap:RetainedEarningsMember 2024-06-30 0001310488 2024-06-30 0001310488 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001310488 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001310488 2023-01-01 2023-03-31 0001310488 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001310488 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001310488 2023-04-01 2023-06-30 0001310488 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001310488 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001310488 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001310488 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001310488 2024-01-01 2024-03-31 0001310488 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001310488 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001310488 2024-04-01 2024-06-30 0001310488 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001310488 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001310488 us-gaap:CommonStockMember 2023-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001310488 us-gaap:RetainedEarningsMember 2023-09-30 0001310488 us-gaap:CommonStockMember 2024-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001310488 us-gaap:RetainedEarningsMember 2024-09-30 0001310488 2020-05-01 2020-05-06 0001310488 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001310488 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001310488 2019-11-01 2019-11-25 iso4217:USD shares iso4217:USD shares false 2024 Q3 --12-31 0001310488 10-Q true 2024-09-30 false 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. NV 74-3078125 2020 General Booth Blvd. Unit 230 Virginia Beach VA 23454 757 306-6090 Yes Yes Non-accelerated Filer false true false 29271755 1635 638 1635 638 1635 638 6261 2649 1913767 1596517 260039 220702 2180067 1819868 2180067 1819868 0.001 0.001 900000000 900000000 29271755 29271755 29271755 29271755 29272 29272 158789302 158781227 -160997006 -160629729 -2178432 -1819230 1635 638 105750 105750 317250 317250 16274 7857 50027 40293 122024 113607 367277 357543 -122024 -113607 -367277 -357543 29271755 29271755 29271755 29271755 29271755 29271755 29271755 29271755 -0.00 -0.00 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -367277 -357543 3612 677 317250 317250 -46415 -39616 8075 39337 39568 47412 39568 997 -48 638 734 1635 686 29271755 29272 158781227 -160157776 -1347277 -130005 -130005 29271755 29272 158781227 -160287781 -1477282 -113931 -113931 29271755 29272 158781227 -160401712 -1591213 -113607 -113607 29271755 29272 158781227 -160515319 -1704820 29271755 29272 158781227 -160629729 -1819230 -130813 -130813 29271755 29272 158781227 -160760542 -1950043 75 75 -114440 -114440 29271755 29272 158781302 -160874982 -2064408 8000 8000 -122024 -122024 29271755 29272 158789302 -160997006 -2178432 <p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zTVqNRTDGcHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 – <span id="xdx_828_zoUiRQP2r0Mi">Organization &amp; Description of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was incorporated in the State of Nevada on December 10, 1999 as Silver River Ventures, Inc. On February 24, 2006, the Company completed the acquisition of BioForce Nanosciences Holdings Inc. (“BioForce”), a Delaware corporation, and changed the corporate name at that time. On May 6, 2020, the Company purchased <span id="xdx_907_ecustom--BusinessAcquisitionEquityInterestsPurchasedNumberOfShares_c20200501__20200506_pdd" title="Number of shares purchased">100,000</span> shares of Element Acquisition Corporation for $<span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesGross_c20200501__20200506_pp0p0" title="Payment to acquire subsidiary">1,000</span> which then became a wholly owned subsidiary. On October 15, 2020, the Company’s wholly-owned subsidiary changed its name from Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc, a Wyoming corporation. On December 14, 2021, the Company’s wholly-owned subsidiary changed its name from BioForce Nanosciences Holdings, Inc., a Wyoming corporation to Element Global Inc., a Wyoming corporation. The Company’s mission is to become a leading provider of vitamin, mineral and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 100000 1000 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zLQbRLrDFrk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 – <span id="xdx_828_z817k4yHGVn6">Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzdjzQwOGk9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zMgq7ymQLx2i">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated balance sheet has been derived from the December 31, 2023 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2024 and 2023, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results of operations expected for the year ending December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zr3mOb1umINg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_zhNcPfWmMlc3">Principles of Consolidation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--UseOfEstimates_z3vmcKy2MBwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zzQXwTESo3s">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zdb90LkDtSql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zqfRWcTyt2B2">Earnings (Loss) per Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z5wmWEGZM65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zlmSfXZJYtC3">Stock-Based Compensation</span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718,<i> Compensation—Stock Compensation,</i> which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values.  The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3reqTF4c7B3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zYLZkonYPBGa">Fair Value of Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates.</p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zqQR8eWEhItl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_z2T4vduINW7g">Revenue Recognition</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company implemented ASC 606, <i>Revenue from Contracts with Customers</i>. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzdjzQwOGk9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zMgq7ymQLx2i">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated balance sheet has been derived from the December 31, 2023 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2024 and 2023, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results of operations expected for the year ending December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zr3mOb1umINg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_zhNcPfWmMlc3">Principles of Consolidation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--UseOfEstimates_z3vmcKy2MBwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zzQXwTESo3s">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zdb90LkDtSql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zqfRWcTyt2B2">Earnings (Loss) per Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z5wmWEGZM65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zlmSfXZJYtC3">Stock-Based Compensation</span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718,<i> Compensation—Stock Compensation,</i> which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values.  The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3reqTF4c7B3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zYLZkonYPBGa">Fair Value of Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates.</p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zqQR8eWEhItl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_z2T4vduINW7g">Revenue Recognition</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company implemented ASC 606, <i>Revenue from Contracts with Customers</i>. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_807_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zcUDNVdBXNih" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 – <span id="xdx_829_z2MjwroZzzjf">Recently Issued Accounting Standards</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements, including the new lease standard. The Company does not have any leases and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zT06q30ybVnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 – <span id="xdx_827_zy6euzdmETu2">Going Concern</span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has reported recurring losses from operations and has net current liabilities and an accumulated deficit. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While the Company is attempting to continue operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management believes that the actions presently being taken to further implement the Company’s business plan; to expand sales with a dynamic marketing campaign and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. During the nine months ended September 30, 2023 due to lack of revenues the officers of the Company paid for all expenses through loans to the Company. This allowed the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zVEvg3A8vlHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 – <span id="xdx_821_z0GjQaHdmBJk">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s Director, Secretary and Acting CFO, Richard Kaiser, is the operator of Yes International, a full-service investor relations firm. He handles duties of the Company regarding his officer capacities as the Secretary and Acting CFO, but also provides investor relations services through Yes International for the Company at no charge.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September 30, 2024 and 2023, two board of directors paid expenses of the Company in the amount of $<span id="xdx_905_eus-gaap--OtherExpenses_c20240101__20240930_pp0p0" title="Expenses">39,338</span> and $<span id="xdx_908_eus-gaap--OtherExpenses_c20230101__20230930_pp0p0" title="Expenses">39,568</span>, respectively. Due to related parties was $<span id="xdx_902_ecustom--DueToRelatedParties_c20240930_pp0p0" title="Due to related parties">260,039</span> and $<span id="xdx_901_ecustom--DueToRelatedParties_c20230930_pp0p0" title="Due to related parties">213,664</span> at September 30, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 39338 39568 260039 213664 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zaIe3lZaWSL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 – <span id="xdx_821_zCticTDYj6aj">Stock</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preferred stock consists of <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20240930_pdd" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20231231_pdd" title="Preferred stock, shares authorized">100,000,000</span></span> shares authorized at $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_c20240930_pdd" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20231231_pdd" title="Preferred stock, par value">0.001</span></span> par value. <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares authorized">10,000,000</span></span> of these preferred shares have been separately allocated to Series A Preferred. <span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20240101__20240930" title="Preferred stock conversion basis">Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock.</span> At September 30, 2024 and December 31, 2023, there were -<span id="xdx_909_eus-gaap--PreferredStockSharesIssued_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesIssued_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares outstanding">0</span></span></span></span>- Series A Preferred shares issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock consists of <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20240930_zdXLdcmoipSe" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z8xb1jXEQ6ig" title="Common stock, shares authorized">900,000,000</span></span> shares authorized at $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240930_z55VR2bgweAb" title="Common stock, par or stated value per share"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zjONeU1Ubdgh" title="Common stock, par or stated value per share">0.001</span></span> par value. On November 25, 2019, the board of directors approved a <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20191101__20191125" title="Reverse stock split">5 to 1 reverse split.</span> At September 30, 2024 and December 31, 2023, there were <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20240930_zzw6ll7Kgbi5" title="Common stock, shares, issued"><span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20231231_zYyMQV9oBeYb" title="Common stock, shares, issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20240930_zARnzF6amp3g" title="Common stock, shares, outstanding"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zFzqJutwIAzb" title="Common stock, shares, outstanding">29,271,755</span></span></span></span> shares issued and outstanding, respectively.</p> 100000000 100000000 0.001 0.001 10000000 10000000 Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock. 0 0 0 0 900000000 900000000 0.001 0.001 5 to 1 reverse split. 29271755 29271755 29271755 29271755 false false false false